{"id":"voglibose-metformin","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Gastrointestinal disturbance (diarrhea, flatulence, abdominal discomfort)"},{"rate":"<1","effect":"Lactic acidosis (metformin-related, rare)"},{"rate":null,"effect":"Hypoglycemia (when combined with other agents)"},{"rate":"5–15","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL476960","moleculeType":"Small molecule","molecularWeight":"267.28"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Voglibose is an α-glucosidase inhibitor that delays carbohydrate digestion and glucose absorption in the small intestine, reducing postprandial blood glucose spikes. Metformin is a biguanide that decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity. Together, they provide complementary mechanisms to improve glycemic control in type 2 diabetes.","oneSentence":"Voglibose inhibits intestinal α-glucosidases to slow glucose absorption, while metformin reduces hepatic glucose production and improves insulin sensitivity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:54:50.612Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05688332","phase":"PHASE3","title":"Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients","status":"UNKNOWN","sponsor":"University of Zambia","startDate":"2023-08","conditions":"Diabetes Mellitus Type 2 Without Complication","enrollment":118},{"nctId":"NCT02049814","phase":"PHASE4","title":"Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":494},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT02097342","phase":"PHASE4","title":"Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus, Insulin Sensitivity/Resistance","enrollment":30},{"nctId":"NCT00970528","phase":"PHASE4","title":"Glucose Reduction by Early Acarbose Treatment in Basal Insulin","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":124}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"PYREXIA"},{"count":1,"reaction":"THROMBOCYTOPENIA"}],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Voglibose + Metformin","genericName":"Voglibose + Metformin","companyName":"University of Zambia","companyId":"university-of-zambia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Voglibose inhibits intestinal α-glucosidases to slow glucose absorption, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}